Solventum Corp Q3 FY2025 earnings call

Transformation and Momentum - Executing a 3-phase transformation plan with momentum from commercial restructuring, innovation revitalization, and portfolio optimization. - Transform for the Future initiative: A multiyear global initiative to reshape cost structure, improve operational efficiency, and fuel innovation. - Portfolio Optimization: Progress on SKU rationalization, successful sale of Purification and Filtration business, positioning for offensive M&A. - Business Segment Performances: MedSurg strong in Advanced Wound Care; Dental Solutions driven by innovation; HIS by revenue cycle management.

Overall, Solventum's business mix in the third quarter was largely as expected, with growth rates of Dental Solutions and HIS better than expected. The largest segment, MedSurg, delivered $1.2 billion in sales, an increase of 1.1% on an organic basis. Within MedSurg, Advanced Wound Care business grew 2.7% led by negative pressure wound therapy, while Infection Prevention and Surgical Solutions was flat in the quarter. Dental Solutions segment delivered higher-than-expected $340 million in sales, an increase of 6.5% on an organic basis. HIS segment contributed higher-than-expected $345 million in sales, an increase of 5.6% on an organic basis, driven by strong performance management and revenue cycle management solutions.

Sales Growth - Raised full-year organic sales growth to the high end of the 2% to 3% range. ### EPS - Increased guidance to a range of $5.98 to $6.08. ### Free Cash Flow - Excluding P&F divestiture impact, free cash flows expected to be in the range of $450 million to $550 million; including divestiture, $150 million to $250 million. ### Transform for the Future - Projected to deliver annual savings of approximately $500 million over 4 years, with reinvestment in areas like sales force and marketing.

• Tariff Headwinds: Still a $60 million to $80 million range for the year, with greater headwind expected in Q4. - Separation and Divestiture: Ongoing separation activities and divestiture impacts on financials and operations.

Q: About the Transform for the Future program and where reinvestment areas lie A: Bryan Hanson states it was contemplated, focused on savings across operations, procurement, etc., with reinvestment in R&D, commercial infrastructure.

Q: Dental sector geographic trends A: Bryan Hanson mentions new products launched globally are gaining traction across regions.

Q: Tariff impact range and free cash flow A: Wayde McMillan explains tariff range remains wide due to dynamic environment; free cash flow guidance adjusted for P&F divestiture but still strong ex-divestiture.

Q: Margin expansion and M&A potential A: Wayde McMillan talks about margin expansion plans to offset tariff headwinds; Bryan Hanson mentions tuck-in M&A opportunities below $1 billion in established markets.